{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:03Z","timestamp":1792813203128,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Several studies suggested that CD30 expression is a favorable prognostic marker in transformed mycosis fungoides (tMF). However, evidence in this field is still unclear. This systematic review and meta-analysis aimed to evaluate the prognostic significance of CD30 in tMF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Electronic databases were searched from their inception to June 2020 for all studies assessing the prognostic value of CD30 in tMF. Pooled hazard ratio (HR) for death was calculated; a P value less than .05 was considered significant. Inconsistency index (I2) was used to assess statistical heterogeneity among studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven studies with 323 patients were included. CD30 expression in tMF was significantly associated with a decreased hazard of death both on univariate (HR, 0.459; 95% confidence interval [CI], 0.319-0.660; P &amp;lt; .001) and multivariate analysis (HR, 0.503; 95% CI, 0.345-0.734; P &amp;lt; .001), and the statistical heterogeneity among studies was null in all analyses (I2 = 0%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>tMF cases with CD30 expression in large cells have a hazard of death two times lower than CD30-negative cases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaa261","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T21:48:01Z","timestamp":1605822481000},"page":"350-355","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic Significance of CD30 in Transformed Mycosis Fungoides"],"prefix":"10.1093","volume":"156","author":[{"given":"Antonio","family":"Travaglino","sequence":"first","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Pathology Section Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Pathology Section Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Varricchio","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Pathology Section Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pignatiello","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Pathology Section Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Baldo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Dermatology Section Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II,\u201d Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II,\u201d Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-220X","authenticated-orcid":false,"given":"Massimo","family":"Mascolo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Pathology Section Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"2023021215114679000_CIT0001","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"2023021215114679000_CIT0002","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/jdv.14614","article-title":"Expression of FK506-binding protein 51 (FKBP51) in mycosis fungoides","volume":"32","author":"Mascolo","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2023021215114679000_CIT0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2023021215114679000_CIT0004","first-page":"1048","article-title":"Lichen striatus histopathologically mimicking mycosis fungoides","volume":"12","author":"Mascolo","year":"2014","journal-title":"J Dtsch Dermatol Ges."},{"key":"2023021215114679000_CIT0005","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood."},{"key":"2023021215114679000_CIT0006","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mpdhp.2016.04.004","article-title":"Unusual variants of mycosis fungoides","volume":"22","author":"Virmani","year":"2016","journal-title":"Diagn Histopathol (Oxf)."},{"key":"2023021215114679000_CIT0007","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000479822","article-title":"Reflectance confocal microscopy as new diagnostic tool in folliculotropic mycosis fungoides","volume":"4","author":"Fabbrocini","year":"2018","journal-title":"Skin Appendage Disord."},{"key":"2023021215114679000_CIT0008","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol."},{"key":"2023021215114679000_CIT0009","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood."},{"key":"2023021215114679000_CIT0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2007.08008.x","article-title":"Transformed mycosis fungoides: clinicopathological features and outcome","volume":"157","author":"Barberio","year":"2007","journal-title":"Br J Dermatol."},{"key":"2023021215114679000_CIT0011","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0609.2006.00809.x","article-title":"Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides","volume":"78","author":"Hallermann","year":"2007","journal-title":"Eur J Haematol."},{"key":"2023021215114679000_CIT0012","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/gcc.20469","article-title":"Common chromosomal abnormalities in mycosis fungoides transformation","volume":"46","author":"Prochazkova","year":"2007","journal-title":"Genes Chromosomes Cancer."},{"key":"2023021215114679000_CIT0013","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pathol.2018.08.008","article-title":"Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression","volume":"50","author":"Wang","year":"2018","journal-title":"Pathology."},{"key":"2023021215114679000_CIT0014","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s12253-020-00848-6","article-title":"Involvement of Helicobacter pylori in ocular adnexa lymphoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol Oncol Res."},{"key":"2023021215114679000_CIT0015","doi-asserted-by":"crossref","first-page":"152864","DOI":"10.1016\/j.prp.2020.152864","article-title":"Hepatitis C virus in MALT-lymphoma of the ocular adnexa","volume":"216","author":"Travaglino","year":"2020","journal-title":"Pathol Res Pract."},{"key":"2023021215114679000_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev."},{"key":"2023021215114679000_CIT0017","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med."},{"key":"2023021215114679000_CIT0018","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/ajcp\/aqaa005","article-title":"Sj\u00f6gren syndrome in primary salivary gland lymphoma","volume":"153","author":"Travaglino","year":"2020","journal-title":"Am J Clin Pathol."},{"key":"2023021215114679000_CIT0019","doi-asserted-by":"crossref","first-page":"152819","DOI":"10.1016\/j.prp.2020.152819","article-title":"Clinical features associated with high pathological grade in primary thyroid lymphoma","volume":"216","author":"Travaglino","year":"2020","journal-title":"Pathol Res Pract."},{"key":"2023021215114679000_CIT0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ajcp\/aqz181","article-title":"Prevalence of Chlamydia psittaci, Chlamydia pneumoniae, and Chlamydia trachomatis determined by molecular testing in ocular adnexa lymphoma specimens","volume":"153","author":"Travaglino","year":"2020","journal-title":"Am J Clin Pathol."},{"key":"2023021215114679000_CIT0021","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ajcp\/aqz145","article-title":"Hashimoto thyroiditis in primary thyroid non-Hodgkin lymphoma","volume":"153","author":"Travaglino","year":"2020","journal-title":"Am J Clin Pathol."},{"key":"2023021215114679000_CIT0022","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11899-020-00583-4","article-title":"Primary cutaneous CD30+ lymphoproliferative disorders: a comprehensive review","volume":"15","author":"Di Raimondo","year":"2020","journal-title":"Curr Hematol Malig Rep."},{"key":"2023021215114679000_CIT0023","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"de Claro","year":"2012","journal-title":"Clin Cancer Res."},{"key":"2023021215114679000_CIT0024","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/cco.2019.01.02","article-title":"Systemic therapy of cutaneous T-cell lymphoma (CTCL)","volume":"8","author":"Alpdogan","year":"2019","journal-title":"Chin Clin Oncol."},{"key":"2023021215114679000_CIT0025","doi-asserted-by":"crossref","first-page":"e12835","DOI":"10.1111\/dth.12835","article-title":"Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin","volume":"32","author":"Goyal","year":"2019","journal-title":"Dermatol Ther."},{"key":"2023021215114679000_CIT0026","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood."},{"key":"2023021215114679000_CIT0027","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)","author":"Horwitz","year":"2020"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/3\/350\/49162351\/aqaa261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/3\/350\/49162351\/aqaa261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T15:12:28Z","timestamp":1676214748000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/156\/3\/350\/6188915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,26]]},"published-print":{"date-parts":[[2021,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaa261","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,3,26]]}}}